Beclomethasone
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Trimbow | — | 2017-07-17 | europa.eu ↗ |
Trials 37 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 27 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06871904 Background | Apr → Dec 2025 | oral submucous fibrosis | Ziauddin University | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05970731 Comparator | Sep 2023 → Oct 2024 | long COVID-19 | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT04937543 Comparator | Jun → Oct 2021 | COVID-19 | UPECLIN HC FM Botucatu Unesp | Completed | No outcome recorded |
| Phase 2 | NCT04294641 Background | May 2021 → Jun 2024 | chronic graft versus host disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT02517099 Comparator | Jun 2015 → Aug 2018 | asthma | Imperial College London | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06657066 Background | Dec 2021 → Apr 2022 | asthma | King Edward Medical University | Completed | No outcome recorded |
| Phase 2/3 | NCT00119496 Comparator | Jul 2005 → Jun 2007 | asthma | University of Glasgow | Completed | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT06234345 Comparator | Sep 2026 → Aug 2028 expected | chronic obstructive pulmonary disease | Eurofarma Laboratorios S.A. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06429475 Comparator | Jun 2024 → Dec 2028 expected | asthma | University of KwaZulu | Recruiting | No outcome recorded |
| Phase 3 | NCT03846570 Comparator | Jan 2019 → Jul 2022 | bronchiectasis | Erasmus Medical Center | Terminated | No outcome recorded |
| Phase 3 | NCT02113072 Background | Apr → Aug 2014 | asthma | Federal University of Pernambuco | Completed | No outcome recorded |
| Phase 3 | NCT01917331 Background | Mar 2014 → Jan 2016 | chronic obstructive pulmonary disease | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT07052942 Comparator | Aug 2025 → Nov 2029 expected | acute asthma | DARTNet Institute | Recruiting | No outcome recorded |
| Phase 4 | NCT06272370 Comparator | Feb → Sep 2024 | asthma, hypersensitivity reaction disease, obstructive lung disease, respiratory tract infectious disorder | DARTNet Institute | Completed | No outcome recorded |
| Phase 4 | NCT05352191 Comparator | Sep 2022 → Jan 2023 | — | Western Norway University of Applied Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT02319564 Comparator | Apr → Oct 2016 | — | University of Calgary | Withdrawn | No outcome recorded |
| Phase 4 | NCT02345993 Comparator | Jan → May 2015 | acute asthma | National Institute of Respiratory Diseases, Mexico | Unknown | No outcome recorded |
| Phase 4 | NCT01741285 Comparator | Apr 2013 → Jul 2015 | asthma | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 4 | NCT01333800 Comparator | Jul → Dec 2010 | asthma | Grünenthal Colombiana S.A. | Completed | No outcome recorded |
| Phase 4 | NCT00962299 Comparator | May 2010 → Jan 2012 | asthma | Princess Amalia Children's Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT01255579 Comparator | Jul 2007 → Dec 2008 | asthma | University of Brescia | Completed | No outcome recorded |
| Phase not applicable6 trials | ||||||
| — | NCT07329946 Background | Sep 2026 → Feb 2027 expected | chronic obstructive pulmonary disease | Pierachille Santus, MD, PhD | Not yet recruiting | No outcome recorded |
| — | NCT07267273 Comparator | Nov 2025 → Feb 2026 overdue | vitiligo | Cairo University | Recruiting | No outcome recorded |
| — | NCT07058259 Background | Nov 2024 → Jun 2025 overdue | chronic obstructive pulmonary disease | Istanbul Medeniyet University | Active not recruiting | No outcome recorded |
| — | NCT02790047 Background | Oct 2016 → Jan 2018 | chronic obstructive pulmonary disease | Khon Kaen University | Unknown | No outcome recorded |
| — | NCT01224951 Comparator | Jan 2011 → Feb 2015 | asthma | Universitaire Ziekenhuizen KU Leuven | Unknown | No outcome recorded |
| — | NCT00775489 Comparator | Jan → Jul 2010 | ocular hypertension | University Health Network, Toronto | Completed | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 64 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Beclomethasone | “participants will use either a combination of budesonide/formoterol or mometasone/formoterol as both controller and rescue therapy or a stand alone inhaled steroid...” NCT06272370 ↗50“The study evaluated the efficacy of beclomethasone dipropionate/formoterol fumarate (BDP/FF) extrafine combination versus fluticasone propionate/salmeterol (FP/S) combination...” PMID 24621109 ↗ Mar 2014 “Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)” NCT01570478 ↗ “Any therapy that is prescribed as per asthma guidelines i.e. beclomethasone, budesonide and salbutamol, montelukast etc” NCT06429475 ↗ “a stand alone inhaled steroid (beclomethasone, budesonide, fluticasone, mometasone, ciclesodine) of their choice” NCT07052942 ↗ “Evaluate the Effects of Formoterol and Beclomethasone Dipropionate Combination Therapy on Small Airways Function” NCT01466712 ↗ “Beclomethasone is a topical corticosteroid that reduces inflammation and provides symptomatic relief in OSF.” NCT06871904 ↗ “Inhaled Fenotereol,Ipratroium Plus Beclomethasone Versus Salmeterol,Tiotropium Plus Fluticasone” NCT05748977 ↗ “inhaled therapy of beclomethasone/formoterol/glycopyrronium (BFG) (100/6/12.5mcg)” NCT04937543 ↗ “Trimbow® (Beclomethasone 100 mcg/Formoterol 6 mcg/Glycopyrronium 12.5 mcg)” NCT06234345 ↗ “Intervention: Drug: Beclomethasone 400 µg HFA per day” NCT03835871 ↗ “Ciclesonide, Beclomethasone, Placebo” NCT01550471 ↗ “Beclomethasone (inhaler)” NCT02790047 ↗ “Beclomethasone” NCT04179461 ↗ |
| Known as | BDP | “BACKGROUND: This study evaluated the lung deposition and the distribution pattern in the airways of a fixed combination of beclometasone dipropionate (BDP) and formoterol...” PMID 29989511 ↗ Jul 2018 |
| Known as | Beclometasone | “Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler(®) Device in Healthy Subjects, Asthmatic Patients, and...” PMID 29989511 ↗ Jul 201811“Triple Therapy (LABA + LAMA + ICS): Patients receive the above combination of LABA and LAMA plus an inhaled corticosteroid (ICS) such as Budesonide, Fluticasone, or Beclometasone.” NCT07058259 ↗ “a corticosteroid (beclometasone) plus a rapid-onset, long-acting β2 agonist (formoterol)” PMID 24321801 ↗ Mar 2013 “beclometasone/formoterol/glycopyrronium 87/5/9 mcg” NCT07329946 ↗ |
| Known as | beclometasone dipropionate | “BACKGROUND: This study evaluated the lung deposition and the distribution pattern in the airways of a fixed combination of beclometasone dipropionate (BDP) and formoterol...” PMID 29989511 ↗ Jul 20181“Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.” NCT01466712 ↗ |
| Known as | beclometasone/formoterol (100/6µg) pMDI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00476268 ↗ |
| Known as | beclomethasone (dipropionate) | “formoterol (fumarate dihydrate) 12 microg - beclomethasone (dipropionate) 200 microg administered BID, per inhalation using '100/6' Metered Dose Inhaler” NCT03846570 ↗ |
| Known as | Beclomethasone Dipropionate,BDP | “Beclomethasone Dipropionate,BDP” NCT02526758 ↗ |
| Known as | QVAR | “Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)” NCT01373008 ↗1“beclomethasone/QVAR, or budesonide/Pulmicort” NCT06272370 ↗ |
| Known as | QVAR 80 HFA | “The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of...” NCT00826748 ↗1“The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of...” NCT00532584 ↗ |
| Modality | Small molecule | “Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection” NCT02351180 ↗ |
| Route | Inhaled | “To test if inhaled glucocorticoids, early in the course of respiratory failure in premature infants, permit normal lung growth and differentiation” NCT00000576 ↗ |